Product
Cohort 5 of Y101D
1 clinical trial
1 indication
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of Y101D, a Recombinant Anti-PD-L1 and TGF-β Bispecific Antibody for Injection, in Patients With Metastatic or Locally Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-03-15